Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Dermatologic 1CNS 1

Conditions

Brain Neoplasms 101Glioblastoma 85Glioma 58Central Nervous System Neoplasms 34Astrocytoma 27Neuroblastoma 26Gliosarcoma 19Breast Neoplasms 19Neoplasms 18Oligodendroglioma 17Recurrence 14Neoplasm Metastasis 13Medulloblastoma 12Ependymoma 11Carcinoma, Non-Small-Cell Lung 11Lymphoma 9Sarcoma 8Osteosarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neuroma, Acoustic 7Meningioma 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Lung Neoplasms 7Hodgkin Disease 7Burkitt Lymphoma 7Wilms Tumor 6Sezary Syndrome 6Neuroectodermal Tumors, Primitive 6Mycosis Fungoides 6

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Growth Hormone-Secreting Pituitary Adenoma × CNS × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡